- Home
- AUPH vs RCUS Comparison
AUPH vs RCUS Comparison
Compare AUPH & RCUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AUPH
- RCUS
- Stock Information
- Founded
- AUPH 1993
- RCUS 2015
- Country
- AUPH Canada
- RCUS United States
- Employees
- AUPH N/A
- RCUS N/A
- Industry
- AUPH Biotechnology: Pharmaceutical Preparations
- RCUS Biotechnology: Pharmaceutical Preparations
- Sector
- AUPH Health Care
- RCUS Health Care
- Exchange
- AUPH Nasdaq
- RCUS Nasdaq
- Market Cap
- AUPH 1.1B
- RCUS 1.2B
- IPO Year
- AUPH 1999
- RCUS 2018
- Fundamental
- Price
- AUPH $7.93
- RCUS $11.07
- Analyst Decision
- AUPH Strong Buy
- RCUS Buy
- Analyst Count
- AUPH 3
- RCUS 11
- Target Price
- AUPH $10.33
- RCUS $31.11
- AVG Volume (30 Days)
- AUPH 1.0M
- RCUS 1.1M
- Earning Date
- AUPH 02-27-2025
- RCUS 02-25-2025
- Dividend Yield
- AUPH N/A
- RCUS N/A
- EPS Growth
- AUPH N/A
- RCUS N/A
- EPS
- AUPH N/A
- RCUS N/A
- Revenue
- AUPH $220,361,000.00
- RCUS $263,000,000.00
- Revenue This Year
- AUPH $36.97
- RCUS $127.65
- Revenue Next Year
- AUPH $16.43
- RCUS N/A
- P/E Ratio
- AUPH N/A
- RCUS N/A
- Revenue Growth
- AUPH 38.72
- RCUS 119.17
- 52 Week Low
- AUPH $4.71
- RCUS $10.63
- 52 Week High
- AUPH $10.67
- RCUS $20.31
- Technical
- Relative Strength Index (RSI)
- AUPH 47.47
- RCUS 34.34
- Support Level
- AUPH $7.50
- RCUS $10.63
- Resistance Level
- AUPH $8.12
- RCUS $13.49
- Average True Range (ATR)
- AUPH 0.27
- RCUS 0.77
- MACD
- AUPH 0.02
- RCUS -0.13
- Stochastic Oscillator
- AUPH 53.49
- RCUS 13.88
About AUPH Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company. It provides products for patients suffering from serious diseases with a high unmet medical need. The firm is developing LUPKYNIS (voclosporin), an investigational drug, for the treatment of lupus nephritis (LN), and others. Geographically, it derives maximum revenue from the United States.
About RCUS Arcus Biosciences Inc.
Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.